Biopharmaceutical companies must invest strategically for patient assistance programs to remain viable. That means finding the right partner. The number of uninsured Americans is on the rise for the first time since the Affordable Care Act took effect; 27.5 million had no he … Read More »

Authored by Dr. Hilde Vanaken – Sr. Industry Advisor, TCS Life Sciences and Healthcare Provided by Tata Consultancy Services (https://www.tcs.com/advanced-drug-development) Since time immemorial, the clinical trials process has been principally driven by a site-centric appro … Read More »

Authors – Dr. Ashish Indani, Aparna Patkar, Devraj Goulikar, Prita Venkateswaran and Divya Vasudevan Introduction The horizon of Artificial Intelligence (AI) is broadening in every field with its presence now felt in the medical field as well. The application of AI now cater … Read More »

“Data is the new oil”, but only analytics-ready data is a real business asset and everyone knows this. However, absence of a cohesive strategy to incorporate cloud platform and data lakes, integrating and consolidating data warehouses, data hubs, and databases as a single so … Read More »

Adoption of an omnichannel environment by the life sciences industry is driving a huge shift towards digital customer engagement and improved customer experience. Making high-quality content available to new channels with speed and at scale, however, has created a challenge … Read More »

By Angela Qu, Senior Director, Biomarkers & Genomic Medicine, Parexel and Todd Shuster, Vice President and Global Therapeutic Area Head, Oncology/ Hematology, Parexel Rapid progress in genomic sequencing, biomarker identification, data capture and analytics have helped t … Read More »

By Dr. Ashish Indani, Devraj Goulikar, Akhil Nair, Pratibha Potare, Dr. Sonal More Download the full article in its original form using the link at the bottom. Introduction Over the last decade, social media, which is at the peak of freedom of expression, has gained immense … Read More »

By: Michelle Hoiseth, Chief Data Officer, PAREXEL and Leanne Larson, Corporate Vice President and WW Head, Real-World Evidence, PAREXEL The current process of drug development is on an unsustainable path forward. The system is inefficient, lengthy and costly. Despite the ris … Read More »

Many, if not most, patients who are treated for cancer or leukemia successfully clear their disease and achieve what is called “remission.” Unfortunately, in most types of cancer, more than half of those who are in remission then go on to relapse; i.e. the cancer returns.  C … Read More »

A sizeable population of physicians in US is now demanding Real World Evidence (RWE) from the pharma industry in order to move prescriptions. This was revealed in the latest edition of PharmaFutureTM Digital Savvy HCP Survey. Physicians are moving the traditional information … Read More »

By: Kathleen Hoffman, PhD MSPH Recently, an industry client asked Inspire to conduct an exploratory social listening project to learn more about patients living with a rare immune disorder. In patients’ real-world online conversations, we identified a focus on dietary change … Read More »

by Martin Roessner, MS, Corporate Vice President, Biostatistics, PAREXEL The current state of pharmaceutical drug development is not on a sustainable path forward. Many experts believe that the process is inefficient, lengthy and costly. The average time it takes to bring a … Read More »

By Jamie Peck, Managing Director, iON Life sciences is a data-driven market, from clinical data to real-world evidence. Healthcare systems, HCPs, advocacy groups, and patients seek relevant, credible, and actionable information to inform decision-making. Traditionally, conte … Read More »

By: Sy Pretorius, Chief Scientific & Medical Officer, PAREXEL Drug development today is facing serious challenges. The way new treatments are brought to market has become increasingly inefficient, lengthy and costly, with a high likelihood of failure. Meanwhile, pressure … Read More »

Perhaps the single most important consideration in selecting a site is whether it can make its enrollment. Many don’t; in fact, 20-25 percent of all clinical studies close because they fail to meet enrollment targets.1 For decades, sponsors have found their “best fit” sites … Read More »